This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Change Healthcare (CHNG) Q1 Earnings Miss, Revenues Beat
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal first-quarter results benefit from solid performance across Software and Analytics, Network Solutions and Technology-Enabled segments.
McKesson (MCK) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2022 results benefit from strong performance across all segments.
Zacks.com featured highlights include: Encompass Health, ON Semiconductor, Kimco Realty, LKQ Corp and Saia
by Zacks Equity Research
Zacks.com featured highlights include: Encompass Health, ON Semiconductor, Kimco Realty, LKQ Corp and Saia
DaVita (DVA) Beats on Q2 Earnings, Raises 2021 EPS View
by Zacks Equity Research
DaVita's (DVA) strength in dialysis patient service revenues drives its Q2 top line.
PacBio's (PACB) Q2 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
PacBio (PACB) sees strength in Q2 product revenues, led by robust consumable sales.
CVS Health (CVS) Q2 Earnings Beat Estimates, EPS View Up
by Zacks Equity Research
CVS Health (CVS) Q2 adjusted EPS drops year over year on escalating costs and expenses which are putting pressure on margins.
Avanos Medical (AVNS) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Avanos Medical's (AVNS) second-quarter 2021 results gains from strength in Pain Management segment.
Charles River (CRL) Q2 Earnings Beat Estimates, 2021 View Up
by Zacks Equity Research
Robust performance by all three segments drove Charles River's (CRL) revenues in the second quarter.
5 Best Stocks With Upgraded Broker Ratings Worth Investing In
by Swayta Shah
By following broker ratings upgrades, you can easily find attractive and profitable stocks. So, we choose Encompass Health (EHC), ON Semiconductor (ON), Kimco Realty (KIM), LKQ Corporation (LKQ) and Saia (SAIA) as these have witnessed ratings upgrade.
AmerisourceBergen (ABC) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter results benefit from segmental growth.
Myriad Genetics (MYGN) Q2 Earnings Beat, Gross Margin Rises
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q2 sales despite a challenging business environment.
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Zimmer Biomet (ZBH) sales improve across all its operating segments and geographies on recovery from the pandemic in the months of the second quarter.
Henry Schein (HSIC) Q2 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Strengthening demand in the global dental and medical markets drove Henry Schein's (HSIC) revenues in the second quarter.
Bruker (BRKR) Q2 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Bruker (BRKR) reports better-than-expected revenues for the second quarter of 2021 on strong segmental performance driving the top line.
Encompass Health (EHC) Beats on Q2 Earnings, Hikes '21 View
by Zacks Equity Research
Encompass Health's (EHC) second-quarter results highlight growing revenues stemming from strong segmental performances, partly offset by elevated costs.
Zacks.com featured highlights include: Encompass Health, Celanese Corp, Salesforce, Ovintiv and Expeditors International of Washington
by Zacks Equity Research
Zacks.com featured highlights include: Encompass Health, Celanese Corp, Salesforce, Ovintiv and Expeditors International of Washington
Encompass Health (EHC) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of 15.84% and 1.51%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Ecolab (ECL) Q2 Earnings & Revenues Beat Mark, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performances across majority of its segments drive its Q2 sales despite pandemic-led business challenges.
PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) second-quarter results benefit from strong segmental performance.
5 Top Stocks With Impressive Sales Growth to Buy Right Away
by Swayta Shah
Sales growth is important for the survival of any business. Let's check Encompass Health (EHC), Celanese (CE), salesforce.com (CRM), Ovintiv (OVV) & Expeditors International (EXPD) that are likely to witness solid top-line growth.
EHC or AMED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. AMED: Which Stock Is the Better Value Option?
Is a Surprise Coming for Encompass Health (EHC) This Earnings Season?
by Zacks Equity Research
Encompass Health (EHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in the Cards for Universal Health's (UHS) Q2 Earnings?
by Zacks Equity Research
Universal Health's (UHS) second-quarter results are likely to reflect improving revenues stemming from growing patient admissions, partly offset by high costs.
Encompass Health (EHC) Continues to Boost Presence in Florida
by Zacks Equity Research
Encompass Health (EHC) plans to construct an inpatient rehabilitation hospital in Florida in a bid to offer improved health outcomes across the state.
Encompass Health (EHC) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Encompass Health (EHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.